Search

OBJECTIVE: To probe into the effects of Jianpi Huatan Xiaoying decoction on autoimmunity, swallowing function and serum Macrophage Inflammatory protein 1α (MIP-1α), soluble interleukin receptor (sIL-2R) and thymidine kinase 1 ( S-TK1) in patients with thyroid dysfunction induced by immunotherapy of lung cancer. METHODS: Totally 88 patients with lung cancer admitted into the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from Feb. 2020 to Feb. 2022 were extracted to be divided into the control group and the study group via the random number table method. Forty-four patients in the control group were treated with PD-1/ PD-L1 immune checkpoint inhibitor combined with conventional chemotherapy, while 44 patients in the study group received Jianpi Huatan Xiaoying decoction on the basis of the control group. Before and after treatment, immunoglobulin M (IgM), T lymphocyte subsets CD4 +, CD8 +, MIP-1α, SIL-2R, free thyroxin (FT4), thyroid stimulating hormone (TSH), total triiodothyronine (TT3), S-TK1, anti thyroglobulin antibody (TGAb), and thyroid receptor antibody (TRAb) levels were measured. Wata drinking water test was used to determine the swallowing function of patients. The patients were evaluated with the EORTC QLQ-C30. Adverse drug reactions of two groups were compared. RESULTS: After treatment, the levels of IgM and CD4 + in the study group were significantly higher than those in the control group, the levels of CD8 + were significantly lower than those in the control group, the levels of TT3 were significantly higher than those in the control group, the levels of TSH, TGAb and TRAb were significantly lower than those in the control group, the levels of MIP-1α, sIL-2R and S-TK1 were significantly lower than those in the control group, and the scores of swallowing function were significantly lower than those in the control group, the EORTC QLQ-C30 score was significantly higher than that of the control group, with statistically significant differences (P<0. 05). The incidence of adverse drug reactions in the study group was 6. 82% (3 / 44), significantly lower than 29. 55% (13 / 44) in the control group, the difference was statistically significant (P<0. 05). CONCLUSIONS: Jianpi Huatan Xiaoying decoction in the treatment of patients with thyroid dysfunction induced by immunotherapy of lung cancer can reduce the immune function injury of patients, improve the abnormal thyroid function, improve the levels of autoimmune antibodies, decrease the reduced swallowing function of patients, improve the quality of life, and reduce adverse drug reactions. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To systematically evaluate the efficacy and safety of Yiguanjian decoction combined with conventional western medicine in the treatment of ascites induced by liver cirrhosis. METHODS: CNKI, VIP, Wanfang Data, Embase, Web of science, PubMed and Clinical Trials databases were retrieved to collect randomized controlled trials that met the screening criteria (the control group received conventional western medicine, while the observation group received Yiguanjian decoction on the basis of control group ), the search time was from the establishment of the database until Feb. 2023. The Cochrane Collaboration Network bias risk assessment was used for quality assessment, and Meta-analysis was performed by using RevMan 5. 4 software. RESULTS: Totally 15 articles were enrolled, including 1 147 patients. Meta-analysis showed that compared with the control group, the treatment regimen in the observation group could improve the total effective rate (RR = 1. 31,95%CI = 1. 24-1. 40,P<0. 000 01) and reduce abdominal circumference (MD = - 8. 26,95% CI = - 10. 44-- 6. 09,P < 0. 000 01), decrease body mass (MD= -6. 86,95%CI = -8. 23--5. 48,P<0. 000 01), increase 24 h urine volume (MD = 465. 38,95%CI = 351. 27- 579. 48,P<0. 000 01), and shorten disappearance time of ascites (MD= -7. 29,95%CI = -13. 97--0. 61,P = 0. 03), and improve liver function. Meanwhile, the incidence of adverse drug reactions in the observation group decreased. CONCLUSIONS: Yiguanjian decoction can improve the efficacy of conventional western medicine treatment of cirrhotic ascites, with few adverse drug reactions. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To analyze the efficacy of glucocorticoid combined with human immunoglobulin in the treatment of children with Kawasaki disease (KD) and its effects on helper T lymphocyte (Th) 1/ Th2 and growth differentiation factor-15 (GDF-15) levels in peripheral blood. METHODS: Totally 83 children with KD admitted into the pediatrics department in this hospital from Jan. 2018 to Jan. 2021 were selected as observation subjects and were divided into the combination group (42 cases) and control group (41 cases) according to the odd or even admission number, both groups were given human immunoglobulin + aspirin, while the combination group was treated with glucocorticoid based on that basis. The efficacy was evaluated after 1 week of treatment, the durations of fever, duration of human immunoglobulin injection, lengths of stay and hospital costs of both groups were collected; the changes of laboratory indexes (white blood cell count, platelet count, hematokrit, C-reactive protein, serum albumin, total bilirubin and direct bilirubin) were measured before treatment and after 1 week of treatment; the changes of Th1/ Th2 cell ratio and GDF-15 level were detected before and after treatment; the incidences of adverse drug reactions such as urinary tract infection, electrocardiographic abnormality and blood glucose disorders of the two groups were collected. RESULTS: The total effective rate of the combination group was 90. 48% (38/42), which was higher than that of the control group (73. 17%, 30/41), with statistically significant difference (χ² = 4. 196, P = 0. 041). The combination group had shorter duration of fever, duration of human immunoglobulin injection and length of stay than those of the control group (t =-3. 924, -3. 644 and -3. 644, all P<0. 01), and the hospital cost of the combination group was less than that of the control group (t =-11. 871, P<0. 01), with statistically significant differences. There were no statistical significance in differences in laboratory indexes between two groups before and after treatment (P>0. 05). After 1 week of treatment, the Th1 cells proportion and the Th1/ Th2 ratio of the combination group were higher than those of the control group, while the Th2 cells proportion and GDF-15 level of the combination group were lower than those of the control group (P <0. 05); the difference values of Th1, Th2 and Th1/ Th2 before and after treatment were higher in the combination group than those in the control group (P<0. 05), with statistically significant difference. The incidences of total adverse drug reactions of the control group and the combination group were respectively 26. 83% (11/41) and 21. 43% (9/42), with no statistically significant difference (χ² = 0. 331, P = 0. 565). CONCLUSIONS: The overall effect of glucocorticoids combination with human immunoglobulin in the treatment of children with KD is better than that of human immunoglobulin alone, which can improved Th2 cell activation, maintained Th1/ Th2 balance and reduced GDF-15 level. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To probe into the effects of Shenxiong glucose combined with furosemide on levels of heart type-fatty acid binding protein (h-FABP ) and serum N-terminal B-type pro brain natriuretic peptide (NT-proBNP) in patients with chronic obstructive pulmonary disease (COPD) complicated with cor pulmonale. METHODS: A total of 120 patients with COPD complicated with pulmonary heart disease admitted into Shijiazhuang Hospital of Traditional Chinese Medicine from May 2020 to May 2021 were selected and divided into observation group and control group via the random number table, with 60 cases in each group. The control group was treated with furosemide, while the observation group was given Shenxiong glucose combined with furosemide. The therapeutic effect, the h-FABP and NT-proBNP levels, and the cardio-pulmonary function before and after treatment were compared between two groups, and the incidences of adverse drug reactions of the two groups were observed. RESULTS: The total effective rate of the observation group was 93. 33% (56 / 60), which was significantly higher than that of the control group (80. 00%, 48 / 60), with statistically significant difference (P<0. 05). Compared with before treatment, the h-FABP and NT-proBNP levels of both groups were lower after treatment, and those of the observation group were significantly lower than the control group, with statistically significant differences (P<0. 05). Compared with before treatment, the cardiac output, ejection fraction and stroke volume of both groups were higher after treatment, and those of the observation group were significantly higher than the control group, with statistically significant differences (P<0. 05). Compared with before treatment, the forced vital capacity, forced expiratory volume in 1 s and arterial partial pressure of oxygen of both groups were higher after treatment, and those of the observation group were significantly higher than the control group, with statistically significant differences (P < 0. 05). The incidence of adverse drug reactions of observation group was 6. 67% (4 / 60), which was significantly lower than that of the control group (28. 33%, 17 / 60), with statistically significant difference (P<0. 05). CONCLUSIONS: Shenxiong glucose combined with furosemide in the treatment of patients with COPD complicated with PHD has good curative effect and high safety, which can reduce the h-FABP and NT-proBNP levels, and improve the cardio-pulmonary function. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To explore the intervention of compound Kushen injection combined with gefitinib on hypercoagulable state in patients with advanced non-small cell lung adenocarcinoma. METHODS: Ninety patients with non-small cell lung adenocarcinoma who were biochemical reported as hypercoagulable state in Center Hospital of Liaoyang from Jun. 2018 to May 2021 were randomly divided into the observation group and the control group, with 45 cases in each group. Patients in the two groups were treated with gefitinib, the observation group was given compound Kushen injection for 2 weeks (14 d) as a course, and both groups were treated with 4 courses. Coagulation changes [plasma prothrombin time (PT), activated partial thromboplastin time (APTT), prothrombin time (TT) and fibrinogen ( FIB)], coagulation metabolite changes [ D-dimer, fibrin degradation product ( FDP ), platelet count (PLT), platelet pressure product (PCT) and platelet aggregation rate (PAg)], hemodynamic indicators (erythrocyte aggregation indicator, hematocrit, capillary plasma viscosity, whole blood viscosity low shearing and whole blood viscosity high shearing) before and after treatment in two groups were observed, the incidence of adverse drug reactions was recorded. RESULTS: After treatment, the PT, APTT and FIB levels in the observation group were higher than those in the control group, while the TT in the observation group was shorter than that in the control group, and there were significant differences in the levels of APTT, TT between the two groups (P<0. 05);the levels of D-dimer, FDP, PLT, PCT and PAg in the observation group were lower than those in the control group, and there were significant differences in the levels of D-dimer, FDP and PAg between the two groups (P<0. 05);the hemodynamic indicators (erythrocyte aggregation indicator, hematocrit, capillary plasma viscosity, whole blood viscosity low shearing and whole blood viscosity high shearing) of the observation group were significantly lower than the control group, the differences were statistically significant (P<0. 05). The incidence of adverse drug reactions in the observation group was 11. 1% ( 5 / 45), significantly lower than 31. 1% ( 14 / 45) in the control group, with statistically significant differences (P< 0. 05). CONCLUSIONS: For patients with non-small cell lung adenocarcinoma in hypercoagulable state, the combination of compound Kushen injection and gefitinib has significant therapeutic effect, and can improve the hypercoagulability of patients with non-small cell lung adenocarcinoma. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To probe into the effect of Compound cantharis capsules on gastrointestinal hormone and Th1/Th2 immune balance in patients with hilar cholangiocarcinoma after surgery. METHODS: Totally 86 patients with hilar cholangiocarcinoma received surgery admitted into the Affiliated Hospital of Hebei University of Engineering from Jun. 2018 to Jul. 2020 were selected and divided into observation group and control group via random number table, with 43 cases in each group. The control group was given conventional processing after surgery, while the observation group was treated with Compound cantharis capsules for 2 weeks since the second day after treatment based on the control group. Recovery of gastrointestinal function after surgery, levels of gastrointestinal hormone, peripheral blood Th1-like cytokines[including interleukin 2 (IL-2), interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α) ], Th2-like cytokines[including interleukin 4 (IL-4) and interleukin 10 ( IL-10) ], proportion of Th1 cell and Th2 cell, Th1/Th2, incidences of postoperative complications and adverse drug reactions during treatment were observed. RESULTS: After surgery of cholangiocarcinoma, the recovery time of bowel sounds, the first anal venting and defecation time of patients in the observation group were shorter than those in the control group, with statistically significant differences (P < 0. 05). After treatment, the motilin (MTL) and gastrin (GAS) levels of both groups were significantly higher than those of before treatment, the MTL and GAS levels of observation group were significantly higher than those of the control group; the vasoactive intestinal peptide (VIP) levels of both groups were significantly lower than those of before treatment, and the VIP level of observation group was significantly lower than that of the control group, with statistically significant differences (P < 0. 05). After treatment, the peripheral blood IL-2, IFN-γand TNF-α levels, proportion of Th1 cell and Th1/Th2 value of both groups were significantly higher than those of before treatment, and those of the observation group were significantly higher than the control group; the IL-4 and IL-10 levels and proportion of Th2 cell of both groups were significantly lower than those of before treatment, and those of the observation group were significantly lower than the control group, with statistically significant differences (P <0. 05). The incidence of complications was 32. 56% (14/43) in the observation group, which was slightly lower than41. 86% (18/43) in the control group, the difference was not statistically significant (P > 0. 05). During treatment, the incidences of adverse drug reactions were respectively 60. 47% ( 26/43) in the observation group and 58. 14% (25/43) in the control group, the difference was not statistically significant (P > 0. 05). CONCLUSIONS: The application of Compound cantharis capsules on patients with hilar cholangiocarcinoma after surgery can promote the recovery of gastroenteric function, regulate gastrointestinal hormones, increase the proportions of Th1-like cytokines and Th1 cell, decrease the proportions of Th2-like cytokines and Th2 cell, improve the Th1/Th2 immune balance and reduce postoperative complications, with good safety. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To probe into the effects of liraglutide and glimepiride in the treatment of patients with inadequately glycemic controlled type 2 diabetes with insulin pump and its adverse drug reactions. METHODS: Totally166 patients with type 2 diabetes admitted into Hengshui People’s Hospital from Aug. 2018 to Aug. 2020 were extracted, after 7 d of continuous treatment with subcutaneous insulin pump ( insulin dosage ＞ 0. 7 IU/kg), the blood glucose was still not up to standard. All patients were divided into the research group ( n = 84) and the control group ( n = 82) via the random number table. The control group was treated with glimepiride, while the research group received liraglutide. Peripheral blood biochemical indicators [glycated hemoglobin ( HbA1 c), fasting blood glucose ( FBG), 2 h postprandial blood glucose ( 2 h PG), triglycerides ( TG), total cholesterol ( TC), high-density lipoprotein cholesterol ( HDL-C), low-density lipoprotein cholesterol ( LDL-C), lipoprotein-related phospholipase A2 ( Lp-PLA2) and high-sensitivity C-reactive protein ( hs-CRP) ], insulin-related indicators [fasting insulin ( FINS), homeostasis model assessment of insulin resistance ( HOMA-IR) ], renal function indicators [serum uric acid ( SUA), creatinine ( SCr), urinary protein excretion rate ( UAER) and urine microalbumin/urinary creatine liver ( ACR) ]and vascular function of both lower limbs [intravascular median membrane thickness ( IMT), peak systolic velocity ( PSV)and stenosis rate] and adverse drugs reactions of two groups were recorded before treatment and after treatment of3 months. RESULTS: After treatment of 3 months, the levels of HbA1 c, FBG, 2 h PG, TG, TC, LDL-C, Lp-PLA2 and hs-CRP in two groups were significantly lower than those before treatment, while the levels of HDL-C were significantly higher than those before treatment; compared with the control group, the levels of HbA1 c, FBG, 2 hPG, TG, TC, LDL-C, Lp-PLA2, hs-CRP and other biochemical indicators in the research group decreased significantly, while the levels of HDL-C increased significantly, with statistically significant difference ( P ＜ 0. 05). After treatment of 3 months, the levels of FINS, HOMA-IR and other indicators in two groups were significantly lower than those before treatment, and the levels of FINS and HOMA-IR in the research group were significantly lower than those in the control group, and the differences were statistically significant ( P ＜ 0. 05). After treatment of 3 months, the levels of renal function indicators such as UAER, SCr, SUA and ACR, and vascular function indicators such as IMT, PSV and stenosis rate of two groups were significantly lower than those before treatment; and the levels of the above renal function indicators and vascular function indicators of the research group were significantly lower than those of the control group, the differences were statistically significant ( P ＜ 0. 05). There were no severe adverse drug reactions in two groups after treatment. CONCLUSIONS: The efficacy of insulin pump combined with liraglutide is better than glimepiride in the treatment of patients with type 2 diabetes. Liraglutide has a more significant effect on blood glucose, blood lipids, islet function and renal function, and has higher safety. [ABSTRACT FROM AUTHOR]

BJECTIVE: To systematically evaluate the risk factors for severe thrombocytopenia or bleeding induced by tirofiban.METHODS: PubMed,EMBase,the Cochrane Library,CNKI,CBM,Wanfang and VIP database were retrieved to collect the literature of risk factors for severe thrombocytopenia or bleeding induced by tirofiban.The retrieval time was from the establishment of the database to Feb. 2020. Two researchers independently screened the literature according to the inclusion and exclusion criteria,extracted the data and evaluated the quality. RevMan 5. 3 software was used for Meta-analysis. RESULTS: A total of 10 literature were included,including 2 foreign language literature and 8 Chinese literature,and 10 141 patients were enrolled.A total of 13 exposure factors were screened out.The univariate Meta-analysis results showed that patients’ old age (MD = 6. 23,95% CI = 4. 58-7. 88),emergency percutaneous coronary intervention (OR = 3. 48,95%CI = 2. 25-5. 38),hypertension (OR = 1. 37,95%CI = 1. 08-1. 72),reduced platelet aggregation rate (MD =-8. 91,95% CI =-11. 17--6. 66),reduced platelet count (MD =-21. 93,95%CI =-32. 81--11. 04),reduced serum creatinine (MD = 10. 01,95% CI = 1. 75-18. 27),reduced creatinine clearance (MD =-32. 16,95% CI =-36. 06--28. 25),reduced glomerular filtration rate (MD =-15. 19,95% CI =-19. 11--11. 26) and the combined application of multiple anticoagulants (OR = 0. 89,95%CI = 0. 53-1. 25) were risk factors for severe thrombocytopenia or bleeding induced by tirofiban (P ＜ 0. 05) . Multivariate Meta-analysis results showed that old age (＞65 years),hypertension,emergency percutaneous coronary intervention and reduced glomerular filtration rate (＜60 ml/min) were independent risk factors for severe thrombocytopenia or bleeding induced by tirofiban (P＜ 0. 01) . The results of sensitivity analysis indicated that the stability of the results was good. CONCLUSIONS:Patients should be alert to severe thrombocytopenia or bleeding when using tirofiban. For patients with risk factors,individualized evaluation should be carried out in advance to reduce the occurrence of adverse drug reactions. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To probe into the key points of pharmaceutical care for severe drug-induced thrombocytopenia induced by levofloxacin. METHODS: Clinical pharmacists performed medication analysis and monitoring on patients with severe drug-induced thrombocytopenia, and concluded that thrombocytopenia was most likely induced by levofloxacin sodium chloride injection, the clinicians were advised to stop using the drugs. The clinicians adopted the recommendation and discontinued levofloxacin sodium chloride injection. RESULTS: By discontinuing levofloxacin, along with platelet enhancement and coagulation factor supplement, the condition of the patient eventually improved. CONCLUSIONS: Clinical pharmacists can improve the safety of clinical medication by providing pharmaceutical care for patients. [ABSTRACT FROM AUTHOR]